Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
OSR Holdings, Inc. (NASDAQ:OSRH), a company currently trading at $0.50 and showing signs of being undervalued according to InvestingPro analysis, has amended key agreements with White Lion Capital, LLC, according to a press release statement based on a filing with the Securities and Exchange Commission. The company, with a market capitalization of $10.21 million, has seen its stock price decline by over 95% year-to-date.
On August 10, OSR Holdings entered into Amendment No. 1 to its Note Purchase Agreement with White Lion. The amendment requires OSR Holdings to take all necessary actions to convene a meeting of its stockholders before September 19, 2025. At this meeting, shareholders will be asked to approve several items, including transactions outlined in the Note Purchase Agreement and related agreements, the issuance of all securities to White Lion—including those exceeding the 19.99% cap set by Nasdaq Rule 5635—and matters related to the Equity Line of Credit Agreement dated February 25, 2025.
If OSR Holdings does not take the required actions to convene the meeting and propose approval, it will be considered a material breach of the Note Purchase Agreement. In that case, White Lion would be entitled to $400,000 in liquidated damages, payable immediately in cash. The amendment clarifies that if the company takes the required actions but does not obtain shareholder approval, it will not be considered a breach or default under the agreement.
The company also entered into Amendment No. 1 to its Common Stock Purchase Warrant with White Lion. This amendment clarifies provisions regarding the exchange cap and makes changes to align with the Note Purchase Agreement and the Equity Line of Credit Agreement. These amendments come at a critical time for OSR Holdings, as InvestingPro data reveals the company is quickly burning through cash with a concerning current ratio of 0.18, indicating potential liquidity challenges.
The original Note Purchase Agreement and Common Stock Purchase Warrant were dated May 6, 2025, and filed as exhibits to a previous Form 8-K on May 12, 2025.
OSR Holdings’ common stock and redeemable warrants trade on the Nasdaq Stock Market under the symbols OSRH and OSRHW, respectively.
This information is based on a press release statement contained in the company’s recent SEC filing.
In other recent news, OSR Holdings, Inc. has issued a total of 2,308,382 shares under its structured financing arrangements, including 767,500 shares through an Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund. This issuance represents less than 10% of the company’s registered share capacity. The company is advancing its acquisition of South Korean medical device company Woori IO Co., Ltd., which specializes in noninvasive glucose monitoring technology. Under the proposed acquisition, Woori IO would become a wholly owned subsidiary of OSR Holdings’ Korean affiliate, with shareholders receiving newly issued shares that could be exchanged for OSRH common stock if certain conditions are met.
Additionally, OSR Holdings has appointed Dr. Andreas Niethammer as Chief Medical (TASE:BLWV) Officer of its subsidiary, Vaximm AG. Dr. Niethammer brings over 20 years of experience in cancer immunotherapy and clinical development. Looking ahead, OSR Holdings plans a $50 million security token offering in 2025, which will accept Bitcoin, Tether, and Taekwondo Access Credit as subscription currencies. These developments highlight the company’s ongoing strategic initiatives and financial maneuvers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.